| |
|
|
 |
|
print
|
|
|
|
|
Late-Clinical to Commercial Supply |
| Lonza, with more than 25 years of custom manufacturing experience, is building Asia’s most advanced mammalian cell culture manufacturing facilities for the contract production of biopharmaceutical products, including monoclonal antibodies (mAbs) and other recombinant proteins.
The Singapore project will extend our worldwide custom manufacturing capacity to provide customers with further large-scale manufacturing capacity to successfully commercialize their important products in the global market.
Lonza’s manufacturing facility in Tuas Biomedial Park will commence with cGMP production in 2010 and will have commercial-scale mammalian bioreactor trains and purification facilities to accommodate a wide range of downstream processes. |
|
|
|
|
|
|
|
|
 |
){kind=small}